Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology

Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the publication of a peer reviewed paper titled ‘Treatment of Wilson Disease in Japan: An Insurance Claims Database Study’ in the Japanese Journal of Gastroenterology and Hepatology. Wilson disease (WD) is a hereditary, progressive, severely debilitating disease principally affecting the liver and the central nervous system.